Tribenoside

Cat. No.:	HY-108249
CAS No.:	10310-32-4
Molecular Formula:	$C_{29}H_{34}O_6$
Molecular Weight:	478.58
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Tribenoside is a vasoprotective agent, can be used for the research of hemorrhoids. Tribenoside has mild anti-inflammatory, analgesic, and wound healing properties[1].

In Vitro

Tribenoside (1 nM-100 μM) exhibits cytotoxic effect against HeLa cells with the EC_{50} of 13.74 μM[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line:	HeLa cells
Concentration:	1 nM, 10 nM, 100 nM, 1 μM, 10 μM, 100 μM
Incubation Time:	72 hours
Result:	Reduced HeLa cells viability in a dose-responsive manner.

In Vivo

Tribenoside (oral administration in doses of 500 and 1,200 mg/kg weekly) significantly decreases in the development of osteoporosis[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	male C57 black mice[3]
Dosage:	500 and 1,200 mg/kg weekly
Administration:	Oral administration
Result:	Led to a significant reduction in the overall arthrotic involvement.

REFERENCES

[1]. Yamato Kikkawa, et al. The influence of Tribenoside on expression and deposition of epidermal laminins in HaCaT cells. Biol Pharm Bull. 2010;33(2):307-10.

[2]. Yu-Chen Lo, et al. Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with Repurposing Potential. Sci Rep. 2017 Sep 12;7(1):11261.

[3]. G Wilhelmi, et al. Suitability of the C57 black mouse as an experimental animal for the study of skeletal changes due to ageing, with special reference to osteo-arthrosis and its response to tribenoside. Pharmacology. 1976;14(4):289-96.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA